BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

Merck to Acquire SpringWorks Therapeutics for $3.9 Billion, Strengthening Rare Tumor Leadership

Purchase price of $47 per share in cash represents an enterprise value of €3.0 billion ($3.4 billion), or an equity value of approximately $3.9 bill...

April 28, 2025 | News

Primo Biotechnology Secures PIC/S GMP and GDP Certifications, Strengthening Global Position in Nuclear Medicine

Primo Biotechnology Co., Ltd. ("Primo") proudly announces that its Taoyuan pharmaceutical facility has successfully passed inspection by Taiwan Food and Dr...

April 25, 2025 | News

GC Cell Secures Exclusive Rights to DAAN Biotherapeutics’ Tumor Antigen-Specific Antibody for CAR-T and CAR-NK Therapies

DAAN Biotherapeutics, a leading innovative drug development company specializing in T-Cell receptor (TCR)-based therapies, has signed an exclusi...

April 22, 2025 | News

TGA Approves IFINWIL® for High-Risk Neuroblastoma Treatment in Australia

Norgine is pleased to announce that the Australian Therapeutic Goods Administration (TGA) has approved the registration of IFINWIL® (eflornit...

April 17, 2025 | Regulatory

Clarity Begins Phase II Dosing in SECuRE Trial for Prostate Cancer with Enhanced 67Cu-SAR-bisPSMA Formulation

The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GB...

April 16, 2025 | News

Bristol Myers Squibb’s Opdivo Plus Yervoy Wins FDA Nod as First-Line Treatment for Advanced Liver Cancer

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy® ...

April 14, 2025 | News

Lucence and HKPOS Launch Hong Kong’s First Study on Blood Test for Early Lung Cancer Detection

In a two-year collaboration with HKPOS, 600 lung cancer patients aged 45-74 in Hong Kong will be studied using Lucence's non-invasive liquid biopsy to as...

April 10, 2025 | News

Singapore’s Engine Biosciences and EDDC Launch First-Ever Partnership to Advance Precision Cancer Therapies

This marks the first-ever collaboration between Engine Biosciences and Experimental Drug Development Centre (EDDC),&nb...

April 08, 2025 | News

Daiichi Sankyo and AstraZeneca’s ENHERTU Approved in EU for Earlier Treatment of HER2 Low and Ultralow Breast Cancer

Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free surviv...

April 04, 2025 | News

Lunit Collaborates with U.S. National Cancer Institute to Advance AI-Driven Cancer Research

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a collaboration with the Nationa...

April 01, 2025 | News

Hyundai ADM Bio Penetrium Shows Strong Anti Metastatic Efficacy in TNBC Study

Hyundai ADM Bio (KOSDAQ symbol 187660) announced on the 24th that its first-in-class pseudo-resistance-targeting agent, PenetriumTM, showed significan...

March 28, 2025 | News

Gene Solutions Achieves Landmark Validation for Asia’s First Clinically Proven Multi-Cancer Blood Test, SPOT-MAS

Gene Solutions, a leading biotech company in Asia, proudly announces a groundbreaking achievement in cancer early detection. Common cance...

March 27, 2025 | News

Vaximm Reports Promising Final Data from Phase 2a Trial of Oral Vaccine VXM01 with Avelumab in Recurrent Glioblastoma

Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, announced fina...

March 27, 2025 | News

Turn Bio Acquires ARMMs Technology to Advance Precision Epigenetic Therapies Across More Tissues and Indications

ARMMs brings precision medicine through targeted, non-viral vesicular delivery Synergy of ARMMs and eTurna™ LNP platforms means company can delive...

March 27, 2025 | News

Stay Connected